BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 25089541)

  • 1. Whole genome DNA methylation signature of HER2-positive breast cancer.
    Lindqvist BM; Wingren S; Motlagh PB; Nilsson TK
    Epigenetics; 2014 Aug; 9(8):1149-62. PubMed ID: 25089541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.
    Palomeras S; Diaz-Lagares Á; Viñas G; Setien F; Ferreira HJ; Oliveras G; Crujeiras AB; Hernández A; Lum DH; Welm AL; Esteller M; Puig T
    Breast Cancer Res; 2019 Jul; 21(1):79. PubMed ID: 31277676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.
    Ramos J; Das J; Felty Q; Yoo C; Poppiti R; Murrell D; Foster PJ; Roy D
    Breast Cancer Res Treat; 2018 Nov; 172(2):469-485. PubMed ID: 30128822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-Dependent Glucose Transporter 1 (SGLT1) Stabled by HER2 Promotes Breast Cancer Cell Proliferation by Activation of the PI3K/Akt/mTOR Signaling Pathway in HER2+ Breast Cancer.
    Wang J; Ji H; Niu X; Yin L; Wang Y; Gu Y; Li D; Zhang H; Lu M; Zhang F; Zhang Q
    Dis Markers; 2020; 2020():6103542. PubMed ID: 32377271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells.
    Holm K; Staaf J; Lauss M; Aine M; Lindgren D; Bendahl PO; Vallon-Christersson J; Barkardottir RB; Höglund M; Borg Å; Jönsson G; Ringnér M
    Breast Cancer Res; 2016 Feb; 18(1):27. PubMed ID: 26923702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K/AKT Signaling in Breast Cancer Molecular Subtyping and Lymph Node Involvement.
    Bonin S; Pracella D; Barbazza R; Dotti I; Boffo S; Stanta G
    Dis Markers; 2019; 2019():7832376. PubMed ID: 31781306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors.
    Sunami E; Shinozaki M; Sim MS; Nguyen SL; Vu AT; Giuliano AE; Hoon DS
    Breast Cancer Res; 2008; 10(3):R46. PubMed ID: 18485221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive DNA Methylation and Extensive Mutation Analyses of HER2-Positive Breast Cancer.
    Yamaguchi T; Mukai H; Yamashita S; Fujii S; Ushijima T
    Oncology; 2015; 88(6):377-84. PubMed ID: 25591616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy.
    Yamashita S; Hattori N; Fujii S; Yamaguchi T; Takahashi M; Hozumi Y; Kogawa T; El-Omar O; Liu YY; Arai N; Mori A; Higashimoto H; Ushijima T; Mukai H
    Sci Rep; 2020 Sep; 10(1):15530. PubMed ID: 32968149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer.
    Tommasi S; Karm DL; Wu X; Yen Y; Pfeifer GP
    Breast Cancer Res; 2009; 11(1):R14. PubMed ID: 19250546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA Methylation Patterns Can Estimate Nonequivalent Outcomes of Breast Cancer with the Same Receptor Subtypes.
    Zhang M; Zhang S; Wen Y; Wang Y; Wei Y; Liu H; Zhang D; Su J; Wang F; Zhang Y
    PLoS One; 2015; 10(11):e0142279. PubMed ID: 26550991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells.
    Hosonaga M; Arima Y; Sugihara E; Kohno N; Saya H
    Cancer Sci; 2014 Jul; 105(7):779-87. PubMed ID: 24754246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
    Fujimoto Y; Morita TY; Ohashi A; Haeno H; Hakozaki Y; Fujii M; Kashima Y; Kobayashi SS; Mukohara T
    Sci Rep; 2020 Dec; 10(1):21762. PubMed ID: 33303839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological complete response of HER2-positive breast cancer to trastuzumab and chemotherapy can be predicted by HSD17B4 methylation.
    Fujii S; Yamashita S; Yamaguchi T; Takahashi M; Hozumi Y; Ushijima T; Mukai H
    Oncotarget; 2017 Mar; 8(12):19039-19048. PubMed ID: 28186977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-wide DNA methylation assay reveals novel candidate biomarker genes in cervical cancer.
    Farkas SA; Milutin-Gašperov N; Grce M; Nilsson TK
    Epigenetics; 2013 Nov; 8(11):1213-25. PubMed ID: 24030264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors.
    Klajic J; Fleischer T; Dejeux E; Edvardsen H; Warnberg F; Bukholm I; Lønning PE; Solvang H; Børresen-Dale AL; Tost J; Kristensen VN
    BMC Cancer; 2013 Oct; 13():456. PubMed ID: 24093668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.
    Nencioni A; Cea M; Garuti A; Passalacqua M; Raffaghello L; Soncini D; Moran E; Zoppoli G; Pistoia V; Patrone F; Ballestrero A
    PLoS One; 2010 Feb; 5(2):e9024. PubMed ID: 20126311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Genome-wide analysis of DNA methylation in prostate cancer using the technology of Infinium HumanMethylation450 BeadChip (HM450)].
    Babalyan KA; Sultanov R; Generozov EV; Zakharzhevskaya NB; Sharova EI; Peshkov MN; Vasilev AO; Govorov AV; Pushkar DY; Prilepskaya EA; Danilenko SA; Babikova EA; Larin AK; Govorun VM
    Vopr Onkol; 2016; 62(1):122-32. PubMed ID: 30444590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth suppression of HER2-overexpressing breast cancer cells by berberine via modulation of the HER2/PI3K/Akt signaling pathway.
    Kuo HP; Chuang TC; Yeh MH; Hsu SC; Way TD; Chen PY; Wang SS; Chang YH; Kao MC; Liu JY
    J Agric Food Chem; 2011 Aug; 59(15):8216-24. PubMed ID: 21699261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alu and LINE-1 hypomethylation is associated with HER2 enriched subtype of breast cancer.
    Park SY; Seo AN; Jung HY; Gwak JM; Jung N; Cho NY; Kang GH
    PLoS One; 2014; 9(6):e100429. PubMed ID: 24971511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.